YanXiang (Michael) Wang, MBA, is PATH’s country director for China, overseeing partnerships with Chinese manufacturers to develop and produce low-cost, high-quality health products across vaccines, medical devices, and drugs.
Since 1979, PATH has collaborated with Chinese government agencies, research institutes, nongovernmental organizations, and manufacturers to address the country’s health needs and build its capacity to contribute to global health. Our public-private partnership model for developing health products has been key to reaching several milestones. For example, a vaccine against Japanese encephalitis is the first vaccine made in China to obtain World Health Organization (WHO) prequalification and has reached millions of children throughout Southeast Asia. The Woman’s Condom—a next-generation female condom—received in 2016 prequalification from both WHO and the United Nations Population Fund.
Mr. Wang's career includes more than 25 years of business development and technical experience and leadership in the pharmaceutical sector. Before joining PATH in 2016, he served as an independent consultant and adviser engaging with global and Chinese national companies on pharmaceutical packaging and drug delivery systems, including prefillable syringes, pens, and self-injection devices. Mr. Wang also has held senior positions at GlaxoWellcome (now GlaxoSmithKline) Anti-Infectives, Boehringer Ingelheim, Gerresheimer Bunde GmbH, and Becton Dickinson. Nearly 20 years ago, Mr. Wang led an effort with PATH to introduce the first-ever introduction of a plastic prefillable auto-destructive concept, (now known as the Uniject™ injection system), into the Chinese public market.
Mr. Wang holds a BS from the School of Pharmacy, West China University of Medical Sciences, and an MBA from Beijing University.
Uniject is a trademark of BD.